Treatment with XOR inhibitors, such as allopurinol and febuxostat, has been shown to have numerous therapeutic effects in humans and mice, such as improved endothelial function and reduced cardiovascular disease–related incidents (50), chronic kidney disease progression (51), cancer cachexia and mortality (52), and disuse-mediated muscle atrophy (12–14). Here, XDH is linked to chronic kidney disease.